Nucor Corporation vs Relay Therapeutics Inc. Common Stock — how do they compare? Nucor Corporation trades at $248 (market cap $55.84B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.82B). The key difference: Nucor Corporation is far larger — about 14.6× Relay Therapeutics Inc. Common Stock's market cap, and Nucor Corporation pays a 0.91% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| NUE | RLAY | |
|---|---|---|
Market Cap | $55.84B | $3.82B |
Volume | 848,835 | 4,332,079 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $20.75 |
52-Week Low | $131.78 | $6.03 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $60.25B | $2.93B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.44, down 1.84% on the day, with mixed technical signals showing neutral momentum. The stock has demonstrated strong earnings performance with recent beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue has stabilized around $32.5B after declining from 2022 peaks, while profit margins show recovery signs. Analysts maintain a bullish stance with a $266.88 price target, representing 8% upside potential from current levels.
Nucor presents a balanced investment case with improving fundamentals but faces cyclical steel industry headwinds. The company's dividend king status and strong operational execution support long-term value, while competitive pressures and margin volatility remain key risks. Current valuation appears reasonable with P/E of 19.67 and P/S of 1.57, suggesting potential for moderate growth if steel demand strengthens.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →